Our lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan (Satoreotide), is an antagonist of the somatostatin type 2 receptor (SST2) which is overexpressed in many neuroendocrine tumours. We are developing satoreotide as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment of neuroendocrine cancers, certain aggressive tumours, which currently have few treatment options and a poor prognosis.
Our second more advanced therapeutic product, AT-001 is a novel 123Iodine radiolabeled PARP inhibitor (rPARPi) which will soon enter a Phase 1 clinical study in recurrent glioblastoma patients, an indication of high unmet medical need. Ariceum intends to expand the development of AT-001 into other fast growing PARP expressing tumours.
Through our partnership with UCB Pharma, we will explore new targets to develop first-in-class radiopharmaceuticals to continue expanding our pipeline beyond the two lead assets.
Ariceum, formally Theragnostics, received FDA approval in Feb 2022 for NephroScan, Kit for the Preparation of Technetium Tc 99m Succimer Injection (99mTc-DMSA).
Please visit our booth, #8048, if you are interested in learning more.
Copyright 2018, a2z, Inc. All rights reserved.